Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

67.8K
Overview
67.8K
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

1.6K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

688
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
688

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rat somatic genome editing enables ER+ breast cancer modeling.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Chronotropic index mediates the relationship between lower-limb loss level and 6-minute walk test performance.

Frontiers in sports and active living·2026
Same author

ICAM1high Neutrophils Sculpt Tumor Evolution and Metastasis through Symbiotic Adhesion and Reverse Migration.

Cancer research·2026
Same author

Performance Evaluation of a Novel Non-Invasive Monitoring Device for At-Home Neutropenia Detection in a Multicenter Cancer Cohort.

American journal of hematology·2026
Same author

Scientific highlights and perspectives from the International Inflammatory Breast Cancer Symposium 2025.

Cancer·2026
Same author

Ecotypes of triple-negative breast cancer in response to chemotherapy.

Nature·2026

Related Experiment Video

Updated: Jun 13, 2025

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

8.9K

Solid tumour-induced systemic immunosuppression involves dichotomous myeloid-B cell interactions.

Xiaoxin Hao1,2,3,4, Yichao Shen1,2,4,5,6, Jun Liu1,2,5

  • 1Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.

Nature Cell Biology
|September 12, 2024
PubMed
Summary
This summary is machine-generated.

Solid tumors cause immune suppression, impacting myeloid and T cells. This study identifies two tumor-induced B cell abnormality (TiBA) patterns, TiBA-1 and TiBA-2, linked to bone marrow changes and potentially guiding tailored cancer immunotherapies.

More Related Videos

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.4K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

305

Related Experiment Videos

Last Updated: Jun 13, 2025

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

8.9K
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.4K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

305

Area of Science:

  • Immunology
  • Oncology
  • Cell Biology

Background:

  • Solid tumors induce systemic immunosuppression, primarily affecting myeloid and T cells.
  • B cell involvement in tumor-induced immune suppression is less understood.
  • Understanding B cell dynamics is crucial for comprehensive cancer immunology.

Purpose of the Study:

  • To identify and characterize distinct patterns of tumor-induced B cell abnormalities (TiBA).
  • To investigate the association between TiBA subtypes and myelopoiesis.
  • To explore the clinical relevance of TiBA in triple-negative breast cancer (TNBC) patients.

Main Methods:

  • Analysis of B cell populations and myelopoiesis in tumor-bearing models.
  • Characterization of two distinct TiBA patterns (TiBA-1 and TiBA-2).
  • Correlation of TiBA profiles with clinical outcomes in TNBC patients undergoing immunotherapy.

Main Results:

  • Two novel TiBA patterns, TiBA-1 and TiBA-2, were discovered, both linked to abnormal bone marrow myelopoiesis.
  • TiBA-1 involves niche competition affecting B cell development, while TiBA-2 features early B cell accumulation driven by neutrophils.
  • TiBA-2-associated B cells promote T cell exhaustion, and TiBA profiles in TNBC patients correlate with immunotherapy response.

Conclusions:

  • Tumor-induced systemic changes exhibit significant inter-patient diversity, involving distinct B and myeloid cell abnormalities.
  • TiBA subtypes represent key indicators of immune dysregulation in cancer.
  • Personalized treatment strategies targeting specific B and myeloid cell aberrations are necessary for effective cancer immunotherapy.